Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

[1]  J. Esteve,et al.  Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Norkin,et al.  Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease , 2013, Leukemia.

[3]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Naoe,et al.  A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor , 2011, Leukemia.

[5]  J. Esteve,et al.  Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. , 2010, Blood.

[6]  J. Rowe.  Prognostic factors in adult acute lymphoblastic leukaemia , 2010, British journal of haematology.

[7]  J. Szer,et al.  The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. , 2010, Blood.

[8]  L. Vidal,et al.  Management of adult patients with acute lymphoblastic leukemia in first complete remission , 2010, Cancer.

[9]  J. Baars,et al.  Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. , 2009, Blood.

[10]  W. Leisenring,et al.  Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. , 2008, Blood.

[11]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[12]  J. Panse,et al.  Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) , 2006, Bone Marrow Transplantation.

[13]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[14]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.

[15]  N. Kröger,et al.  Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation , 2006, Bone Marrow Transplantation.

[16]  U. Pichlmeier,et al.  Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications , 2005, Bone Marrow Transplantation.

[17]  J. Hernández-Rivas,et al.  Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. , 2005, Haematologica.

[18]  V. Diehl,et al.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Freund,et al.  Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[20]  I. Fichtner,et al.  Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). , 2003, European journal of cancer.

[21]  C. Sebban,et al.  Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. , 2000, Hematology/oncology clinics of North America.

[22]  M. Dawson,et al.  Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. , 2000, Cancer research.

[23]  J. Klein,et al.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Blokland,et al.  Treosulfan as an alternative conditioning agent in bone marrow transplantation. , 1999 .

[25]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[26]  J. Doroshow,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .

[27]  D. Findley,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. , 1987, Blood.

[28]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. , 1987, Blood.

[29]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[30]  P. Neiman,et al.  Allogeneic marrow grafting for acute lymphoblastic leukemia: leukemic relapse. , 1973, Transplantation proceedings.